BioStock: Sensidose expects sales growth despite drop in Q3

Spotlight-listed Sensidose reports progress in several areas in the third quarter, despite component shortages and other challenges. During the period, important steps were taken in the market expansion preparations, but also in the development of the new dose dispenser OraFID and the reprogramming of MyFID. In addition, Philip Slätis was recruited as COO and Deputy CEO. The company is now looking forward to the coming period with an expectation of sales growth and market expansion. BioStock contacted CEO Jack Spira to know more about the development.

Read the interview with Sensidose's CEO Jack Spira at biostock.se: 

https://www.biostock.se/en/2022/11/sensidose-expects-sales-growth-despite-drop-in-q3/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se